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Original Article
Purpose: To evaluate non-sentinel lymph node (LN) status after sentinel lymph node biopsy (SNB) in patients with breast cancer 
and to identify the predictive factors for disease failure.
Materials and Methods: From January 2006 to December 2007, axillary lymph node (ALN) dissection after SNB was performed 
for patients with primary invasive breast cancer who had no clinical evidence of LN metastasis. A total of 320 patients were treated 
with breast-conserving surgery and radiotherapy. 
Results: The median age of patients was 48 years, and the median follow-up time was 72.8 months. Close resection margin 
(RM) was observed in 13 patients. The median number of dissected SNB was two, and that of total retrieved ALNs was 11. Sentinel 
node accuracy was 94.7%, and the overall false negative rate (FNR) was 5.3%. Eleven patients experienced treatment failure. Local 
recurrence, regional LN recurrence, and distant metastasis were identified in 0.9%, 1.9%, and 2.8% of these patients, respectively. 
Sentinel LN status were not associated with locoregional recurrence (p > 0.05). Close RM was the only significant factor for 
disease-free survival (DFS) in univariate and multivariate analysis. The 5-year overall survival, DFS, and locoregional DFS were 100%, 
96.8%, and 98.1%, respectively.
Conclusion: In this study, SNB was performed with high accuracy and low FNR and high locoregional control was achieved. 
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Introduction
In invasive breast cancer, axillary lymph nodal status is 
considered to be an important prognostic factor for predicting 
clinical outcome. Since the 1990s, sentinel lymph node 
biopsy (SNB) has been performed routinely for evaluating 
axillary lymph node (ALN) status and reducing complications 
of axillary lymph node dissection (ALND). In several studies, 
SNB could accurately predict ALN status in clinically node-
negative breast cancer patients. Only 5%–15% of early breast 
cancer patients with negative sentinel lymph node (SLN) had 
additional ALN metastasis [1-3]. Because ALND increases the 
risk of complications, such as lymphedema, chronic shoulder 
pain, arm weakness and joint dysfunction without survival 
benefit, completion ALND is not routinely performed in SLN-
negative patients [2,4,5]. 
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  In patients with positive SLN, additional ALN involvement 
is observed in 40%–60%. Because additional ALN metastasis 
is considered to be a significant risk factor for disease 
progression, completion ALND is recommended for regional 
control in SLN-positive patients [6]. However, several 
prospective trials have shown that the regional failure rate is 
lower than expected in patients without ALND who received 
SNB only based on the incidence of axillary metastases. No 
survival difference was observed between patients with SNB 
only and patients with SNB and completion ALND or regional 
radiotherapy [7-10]. Based on the result of these clinical trials, 
additional ALND may be minimized in clinically node-negative 
patients with T1 and T2. The purpose of this study was to 
investigate the association between SLN status and ALN status 
in clinically node-negative early breast cancer patients and 
to evaluate the clinical outcomes after SNB and ALND in our 
institution.
Materials and Methods
We retrospectively performed a chart review of primary breast 
cancer patients treated with whole breast radiotherapy at 
our hospital, between January 2006 and December 2007. 
The criteria for entry into this study were as follows: 1) 
pathologically proven invasive breast cancer, 2) no clinical 
evidence of lymph node metastasis, 3) performance of breast-
conserving surgery, SNB, and ALND, and 4) completion of 
whole breast radiotherapy with or without regional node 
irradiation. We excluded patients who were male; had a history 
of breast irradiation, stage IV or recurrent breast cancer and 
who underwent neoadjuvant chemotherapy. A total of 320 
patients were eligible.
  For staging work-up, all patients received mammography, 
ultrasound of breast, abdomen and whole body bone scan. In 
some patients, breast magnetic resonance imaging was done 
for work-up. We defined clinically node-negative (cN0) as a 
no evidence of lymph node metastasis in the preoperative 
imaging study and physical examination. Two patients with 
palpable ALN or typical metastatic lymph node (round shape, 
obliterated hilum) received fine needle aspiration biopsy, and 
the result was negative. SLN detection was only performed 
using the radio-isotope technique. On the day of surgery, 18.5 
MBq (0.5 mCi) 99mTc-Phytate (Korea Atomic Energy Research 
Institute, Daejeon, Korea) diluted in 0.5 mL saline was injected 
at the upper outer subareolar. A lymphatic scintigram was 
obtained for each patient. In the operating room, a hand-held 
gamma detector (Navigator GPS; RMD Inc., Watertown, MA, 
USA) was used to locate the SLNs. Four patients who fail SLN 
detection were excluded from this study. 
  ALND was performed for all patients following SNB. During 
this period, completion ALND performed even if the SLN was 
negative, because surgeons wanted to make sure negative ALN 
after negative SLN. All enrolled patients were staged according 
to the American Joint Committee on Cancer (AJCC) 7th staging 
system. A surgical margin was diagnosed as close if tumor 
were 2 mm or less from postsurgically applied inked margin.
  All analyses were performed using SPSS software ver. 20.0 
Table 1. Patient characteristics
Characteristic No. of patients (%)
Age (yr), median (range)
AJCC stage
    IA  T1N0M0 
    IB   T1N1miM0 
    IIA  T1N1M0 
  T2N0M0 
    IIB   T2N1M0 
    IIIA  T1N2M0 
  T2N2M0 
  T3N1M0 
Estrogen receptor status
    Positive
    Negative 
    Unknown
Progesterone receptor status
    Positive
    Negative 
    Unknown
HER2
    0, 1+, 2+
    3+
    Unknown
Histology
    IDC 
    Other 
Extensive intraductal component
    No 
    Yes 
    Unknown 
Histologic grade
    1
    2
    3
    Unknown 
48 (25–76)
189 (59.1)
13 (4.1)
43 (13.4)
43 (13.4)
21 (6.6)
5 (1.6)
5 (1.5)
1 (0.3)
220 (68.8)
99 (30.9)
1 (0.3)
199 (62.2)
120 (37.5)
1 (0.3)
280 (87.5)
39 (12.2)
1 (0.3)
288 (90.0)
32 (10.0)
246 (76.9)
51 (15.9)
23 (7.2)
71 (22.2)
143 (44.7)
75 (23.4)
31 (9.7)
AJCC, American Joint Committee on Cancer; HER2, human epi-
dermal growth factor receptor 2; IDC, invasive ductal carcinoma.
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(IBM, Armonk, NY, USA). Overall survival (OS), disease-free 
survival (DFS), locoregional DFS (LRDFS) were analyzed using 
the Kaplan-Meyer method and univariate analysis of clinical 
factors influencing each failure were analyzed using the log-
rank test. Multivariate analysis was performed using the Cox-
proportional hazard model. The p-values less than 0.05 were 
considered statistically significant.
Results
1. Patient characteristics
Patient characteristics are shown in Table 1. The median 
age was 48 years (range, 25 to 76 years). According to AJCC 
7th stage, the number of patients with stage IA, IB, IIA, IIB, 
and IIIA was 189 (59.1%), 13 (4.1%), 86 (26.9%), 21 (6.6%), 
and 11 (3.4%), respectively. The most common histologic 
type of tumor was invasive ductal carcinoma (288, 90.0%). 
Estrogen receptor positive, progesterone receptor positive, and 
c-erbB2 3+ was found in 220 patients (68.8%), 199 (62.2%), 
and 39 (12.2%), respectively. In c-erbB2 2+ patients by 
immunohistochemistry, FISH or SISH was done for 7 patients 
(26%). Among them, c-erbB2 amplification by FISH or SISH 
was observed in one patient. Extensive intraductal component 
was found in 51 patients (15.9%). 
2. Treatment characteristics
Treatment characteristics are summarized in Table 2. The 
median number of removed nodes was two (range, 1 to 
16), and positive SLN was found in 69 patients (21.6%). The 
median number of removed ALNs was 11 (range, 1 to 35), and 
additional involved lymph nodes were found in 38 patients 
(11.9%). Among the patients with negative SLN, positive 
conversion in permanent section was shown in two patients. 
Close or positive resection margin (RM) were found in 13 
patients (4.1%). All patients received whole breast irradiation 
with median of 50.4 Gy in 28 fractions, and 313 patients 
(97.8%) received a tumor bed boost with a median dose of 9 
Gy. Treatment included the breast only in 294 patients (91.9%), 
breast and supraclavicular lymph node (SCL) in 26 patients 
with positive axillary node (8.1%), and breast, SCL, and internal 
mammary lymph node in 20 patients with inner/central tumor 
with or without positive axillary node (6.3%). 
  Most patients (300, 93.6%) received systemic treatments; 
chemotherapy alone in 83 patients (25.9%), hormonal 
therapy alone in 81 patients (25.3%), and both in 133 patients 
(41.6%). Among the 219 patients who received chemotherapy, 
doxorubicin and cyclophosphamide (AC) were used in 124 
patients (56.6%); doxorubicin, cyclophosphamide, and 
paclitaxel (ACT) in 64 patients (29.2%), and cyclophosphamide, 
methotrexate, and 5-fluorouracil (CMF) in 17 patients (7.8%). 
Table 2. Treatment characteristics
Characteristic No. of patients (%)
No. of dissected SLNs
    1
    2
    3
    4
    5
    ≥6 
No. of metastatic SLNs
    0
    1
    2
    3
    ≥4 
No. of dissected ALNs
Additional involved nodes
    No  
    Yes  
Close or positive RM
    No  
    Yes  
2 (1–16)
133 (41.6)
85 (26.6)
42 (13.1)
30 (9.4)
14 (4.4)
16 (5.0)
251 (78.4)
51 (15.9)
11 (3.4)
3 (0.9)
4 (1.3)
11 (1–35)
282 (88.1)
38 (11.9)
307 (95.9)
13 (4.1)
Values are presented as median (range) or number (%).
SLN, sentinel lymph node; ALN, axillary lymph node; RM, resec-
tion margin.
Table 3. FNR rate according to the number of dissected SLNs
No. of dissected SLNs No. of patients TN FN TP FNR (%) Accuracy (%)
1 or more
2 or more
3 or more
4 or more
320
187
102
  60
234
136
  70
  40
17
  9
  3
  0
21
12
  9
  7
5.3
4.0
1.3
0
94.7
96.1
98.7
100
SLN, sentinel lymph node; TN, true negative; FN, false negative; TP, true positive; FNR, false negative rate.
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Two hundred fourteen patients who received hormonal 
therapy; tamoxifen in 157 patients (73.4%) and letrozole in 45 
(21.0%).
3. Accuracy and false negative rate of sentinel node biopsy
SNB and ALND were performed in all patients. Sixty-nine 
patients had positive sentinel node, and additional involved 
nodes were shown in 38 patients. Table 3 shows the accuracy 
and false negative rate (FNR) according to the number of 
dissected SLNs. The sentinel node accuracy was 94.7% and the 
FNR was 5.3% in all patients with ALND. The FNR of the biopsy 
decreased as the number of removed lymph nodes increased. 
Specifically, the FNR was 0% when more than four lymph 
nodes were removed. There were 21 true positive, 234 true 
negative, and 17 false negative results.
4. Survival outcomes, patterns of failure, and prognostic 
factors
With a median follow-up of 72.8 months (range, 6 to 91 
months), 11 patients (3.4%) experienced disease progression 
during the follow-up period. The patterns of failure are 
illustrated in Fig. 1. Local recurrence, regional lymph node 
recurrence and distant metastasis were identified in three 
Fig. 1. Patterns of failure. Eleven patients developed treatment 
failure; local recurrence, regional lymph node recurrence, and 
distant metastasis were identified in three patients (0.9%), six 
(1.9%), and nine (2.8%), respectively.
Fig. 2. (A) Overall survival (OS), (B) disease-free survival (DFS), 
and (C) locoregional DFS among all patients. The 5-year OS, DFS, 
and locoregional DFS were 100%, 96.8%, and 98.1%, respectively.
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patients (0.9%), six (1.9%) and nine (2.8%), respectively. 
Locoregional recurrence occurred in six patients. Among them, 
only two patients had locoregional recurrence without distant 
metastasis. The 5-year OS, DFS, and LRDFS were 100%, 96.8%, 
and 98.1%, respectively (Fig. 2). In univariate and multivariate 
analyses, close RM was the only significant factor for lower 
DFS (p = 0.014) (Table 4). Neither SLN nor non-SLN status 
was significantly associated with locoregional recurrence and 
disease recurrence (p > 0.05).
Discussion and Conclusion
ALN status is an important prognostic factor of survival 
outcome and a predictor of regional and systemic recurrence 
in breast cancer. Therefore, complete ALND is routinely 
performed in breast cancer patients regardless of early or 
advanced disease. Generally, eight or more axillary nodes 
should be routinely dissected irrespective of lymph node 
metastasis because many surgeons consider the number of 
dissected ALNs to be associated with accurate evaluation 
of ALN status. Despite the high locoregional and systemic 
control rates after ALND completion, most patients experience 
several complications, such as lymphedema, shoulder pain, 
and numbness. To reduce these complications, SNB was 
demonstrated by Giuliano et al. [11] to be an effective and 
minimally invasive alternative to ALND for identifying lymph 
node status. Thereafter, many studies investigated the efficacy 
and clinical outcomes of SNB, and SNB is now widely used in 
early breast cancer treatment.
  In early breast cancer patients with negative SLN, no further 
ALND is recommended. In the case of sentinel node metastasis, 
most clinical practice guidelines recommend complete ALND. 
Although additional ALN involvement was found in 35%–60% 
of positive SLN patients, the axillary recurrence rate is reported 
to be 0.2%–0.9% for micrometastatic disease of SLN and 
around 1% for macrometastatic disease [9,12-15]. Based on 
these results, the hypothesis that ALN metastatic disease does 
not cause regional recurrence has been accepted. Therefore, 
several randomized phase 3 trials have been performed to 
investigate whether ALND can safely be omitted in early 
breast cancer patients with positive SLN. In the American 
College of Surgeons Oncology Group Z0011 trial, clinically 
node-negative early breast cancer patients with positive SLN 
were randomized to ALND or no ALND groups. At the median 
follow-up of 6.3 years, no difference was observed between 
groups for OS, progression-free survival (PFS) or locoregional 
PFS. The International Breast Cancer Study Group trial 23-01 
trial was designed to determine whether no ALND was inferior 
to ALND in patients with one or more micrometastatic SLN 
with a tumor of maximum 5 cm. After a median follow-up of 
5 years, no difference was found between the ALND and no 
ALND groups for OS or PFS. In both trials, axillary recurrence in 
the no ALND group was about 1%. In the AMAROS trial, ALND 
and axillary radiotherapy were compared. After a follow-up of 
5 years, axillary radiotherapy was equivalent to ALND in OS, 
PFS, and axillary recurrence [7,9,16]. 
Table 4. Univariate and multivariate associations of prognostic 
factors with recurrence-free survival
Variables
No. of 
patients
p-value
Univariate
Multi-
variate
Age (yr)
    <50 
    >50 
T stage
    T1 
    T2 
    T3 
SLN status
    Negative
    Positive
No. of positive LN
    0
    1
    2
    ≥3
EIC
    Yes 
    No 
Close RM
    Yes 
    No 
Molecular subtype
    Luminal A 
    Luminal B 
    Triple negative 
    HER2 
Regional LN irradiation
    Yes 
    No 
Adjuvant systemic treatment
    Yes 
    No 
199
121
250
  69
    1
251
  69
224
  51
  26
  19
  51
246
  13
307
211
  24
  18
  66
  26
294
300
  20
0.463
0.879
0.773
0.013
0.760
0.003
0.633
0.854
0.388
0.221
0.648
0.176
0.727
0.544
0.014
0.384
0.603
0.989
LN, lymph node; EIC, extensive intraductal component; RM, re-
section margin; HER2, human epidermal growth factor receptor 2.
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  In the present study, our institutional practice achieved 
a high locoregional control rate through SNB and ALND. 
The accuracy and FNR of SNB are comparable to previously 
published studies [17,18]. Currently, ALND is not routinely 
performed in patients with negative SLN. Many surgeons 
insist that ALND should be carried out routinely in positive 
SLN patients because additional ALN involvement has been 
found in 35%–60% of patients. But axillary recurrence rate in 
patients with positive SLN was lower than expected in previous 
studies, even if patient underwent breast-conserving surgery 
without ALND. 
  In our institution, SNB was performed with high accuracy and 
low FNR. Sentinel node status was not associated with axillary 
recurrence. High locoregional control was achieved with SNB 
and ALND. Based on these results, axillary dissection might 
be individualized in early breast cancer patients according to 
sentinel node metastasis. 
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